| DIRECT COMPETITOR COMPARISON | |
| VXGN.OB | CVM | EBS | SNY | Industry | | Market Cap: | 18.87M | 174.97M | 443.49M | 101.26B | 176.84M | | Employees: | 3 | 30 | 587 | 98,213 | 94 | | Qtrly Rev Growth (yoy): | N/A | 761.40% | -23.50% | 8.50% | 22.40% | | Revenue (ttm): | N/A | 50.09K | 216.73M | N/A | 42.63M | | Gross Margin (ttm): | N/A | 100.00% | 48.84% | 75.20% | 68.58% | | EBITDA (ttm): | -4.78M | -9.98M | 45.09M | N/A | -7.66M | | Oper Margins (ttm): | N/A | -20,694.52% | 18.45% | N/A | 2.08% | | Net Income (ttm): | -5.34M | -11.10M | 28.36M | N/A | N/A | | EPS (ttm): | -0.161 | -0.090 | 0.905 | N/A | -0.17 | | P/E (ttm): | N/A | N/A | 15.91 | N/A | 17.43 | | PEG (5 yr expected): | N/A | N/A | N/A | 2.61 | 1.01 | | P/S (ttm): | N/A | 3612.44 | 2.06 | N/A | 4.43 |
|
| CVM = CEL-SCI Corp. | | EBS = Emergent BioSolutions, Inc. | | SNY = Sanofi-Aventis | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.48 | -0.65% | 57.17B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.30 | 0.25% | 13.97B | 16.16 | | Genzyme Corp. | GENZ | 49.72 | -0.52% | 13.19B | 28.35 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.62 | 0.06% | 41.95B | 18.03 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.62 | -0.04% | 9.03B | 1033.06 | | Teva Pharmaceutical Industries Limited | TEVA | 53.25 | -1.41% | 46.91B | 48.72 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.93 | 0.08% | 4.03B | 19.55 | | King Pharmaceuticals Inc. | KG | 11.52 | -1.71% | 2.86B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.18 | 1.06% | 5.56B | 111.53 | | Pfizer Inc. | PFE | 18.06 | -2.33% | 145.74B | 15.00 | | Johnson & Johnson | JNJ | 64.37 | 0.02% | 177.60B | 14.06 | | GlaxoSmithKline plc | GSK | 42.64 | -0.26% | 108.09B | 13.45 | | Sanofi-Aventis | SNY | 38.78 | -1.52% | 101.26B | N/A | | Novartis AG | NVS | 55.50 | -0.09% | 126.05B | 16.62 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.36 | -0.14% | N/A | N/A | | AstraZeneca plc | AZN | 46.13 | -0.37% | 66.89B | 9.26 | | Abbott Laboratories | ABT | 53.66 | -0.22% | 83.00B | 14.54 | | Bristol-Myers Squibb Co. | BMY | 25.28 | 0.56% | 50.08B | 13.08 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SNY | | 5-Star Stocks on the Upswing
Mon 2:43pm -
at Motley Fool | | • | SNY | | 50 Million Uninsured Receive Access To Prescription Drugs Under Health Care Reform Bill: PBMs And Pharmacies Benefit According To Leading Research Analyst
Mon 8:09am -
Wall Street Transcript | | • | SNY | | Zacks Bull and Bear of the Day Highlights: Tiffany & Co., Energy Transfer Partners, Eli Lilly & Co., Bristol-Myers Squibb and Sanofi-Aventis
Mon 7:49am -
Zacks.com | | • | SNY | | Baxter Receives H1N1 Vaccine Order
Fri, Dec 4 -
Zacks.com | | • | SNY | | Lilly's Effient Proves Its Worth
Fri, Dec 4 -
Zacks.com | | • | SNY | | Good News for CytRx
Fri, Dec 4 -
Zacks.com | | • | CVM | | Biotech Stock Mailbag: Hemispherx Biopharma
Fri, Dec 4 -
at TheStreet.com | | • | EBS | | Prospecting for Winning Biotechs: Gilead Sciences
Thu, Dec 3 -
at Motley Fool | | • | SNY | | REO Speedwagon, The Game
Thu, Dec 3 -
at Forbes.com | | • | SNY | | Sanofi's Multaq Gains EU Approval
Thu, Dec 3 -
Zacks.com | | • | SNY | | Behind the Business: 3 Questions for Vical
Thu, Dec 3 -
at Motley Fool | | • | SNY | | Don't Doubt The Comcast Deal
Thu, Dec 3 -
at Forbes.com | | • | EBS | | Yes, Virginia, There Are Bullish Speculators
Wed, Dec 2 -
at Forbes.com | | • | CVM | | CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
Tue, Dec 1 -
PR Newswire | | • | EBS | | Former U.K. Health Protection Agency Director Rejoins Emergent BioSolutions to Head Biodefense Business
Tue, Dec 1 -
Business Wire | | • | EBS | | Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
Mon, Nov 30 -
Business Wire | | • | CVM | | Holiday Cheer: Cel-Sci Should Have Good News
Wed, Nov 25 -
at Seeking Alpha | | • | CVM | | Cel-Sci's History of Disappearing Drugs: BioBuzz
Tue, Nov 24 -
at TheStreet.com | | • | EBS | | Corporate Profile Emergent BioSolutions Inc.
Mon, Nov 23 -
WILink | | • | CVM | | Poniard Finds Cash to Keep Lights On: BioBuzz
Mon, Nov 23 -
at TheStreet.com | | • | CVM | | Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz
Mon, Nov 23 -
at TheStreet.com | | | All Headlines for these symbols... |
|
|
|
0.01% Nasdaq 
0.22%
Competitors
